Apathy – a lack of interest or motivation – could predict the onset of some forms of dementia many years before symptoms start, offering a ‘window of opportunity’ to treat the disease at an early stage, according to new research from a team of scientists led by Professor James Rowe at the University of Cambridge.
Frontotemporal dementia is a significant cause of dementia among younger people. It is often diagnosed between the ages of 45 and 65. It changes behavior, language and personality, leading to impulsivity, socially inappropriate behavior, and repetitive or compulsive behaviors.
A common feature of frontotemporal dementia is apathy, with a loss of motivation, initiative and interest in things. It is not depression, or laziness, but it can be mistaken for them. Brain-scanning studies have shown that in people with frontotemporal dementia it is caused by shrinkage in special parts at the front of the brain – and the more severe the shrinkage, the worse the apathy. But, apathy can begin decades before other symptoms, and be a sign of problems to come.
Alzheimer’s disease and other forms of dementia affect millions of older adults in the US—but not equally. Past research has identified risk factors including genes, education, racism, and air pollution, and a growing number of studies now point to noise as another influence on risk of dementia.
Now, a new study co-led by a School of Public Health researcher finds that 10 decibels more daytime neighborhood noise is associated with 36 percent higher odds of mild cognitive impairment and 30 percent higher odds of Alzheimer’s disease.
“We remain in early stages in researching noise and dementia, but the signals so far, including those from our study, suggest we should pay more attention to the possibility that noise affects cognitive risk as we age,” says study first author Jennifer Weuve, associate professor of epidemiology.
Can your eating habits and physical and mental activity lower your risk for developing dementia as you age? Obviously, it is important to learn all we can about how health habits affect the risks for developing dementia, a debilitating decline in memory and other mental abilities. Experts expect the number of people with dementia worldwide to rise to 82 million by 2030 and to over 152 million by 2050.
A team of researchers designed a study to learn more about whether adopting healthier lifestyle habits can help prevent or slow the onset of dementia. It was published in the Journal of the American Geriatrics Society.
The researchers suggest that prevention strategies should focus on lowering dementia risk for people who are starting to experience cognitive decline, specifically subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
The National Institute on Aging and the Alzheimer’s Association are suggesting changes to the research definition of Alzheimer’s disease. There are new criteria to define what Alzheimer’s disease is and who has it — but only as it relates to clinical trials and research, and not the diagnosis in your doctor’s office, according to Jonathan Graff-Radford, M.D. of the Mayo Clinic.
Previously, Alzheimer’s disease dementia was characterized by symptoms such as memory loss and changes in thinking and cognition. And that’s still the case when your doctor diagnoses Alzheimer’s disease dementia.
Falls are the leading cause of fatal injuries in older adults, causing more than 800,000 hospitalizations and about 30,000 deaths in the U.S. every year. Some risk factors are well-known — advanced age, problems with vision or balance, muscle weakness — but an under-recognized factor is early Alzheimer’s disease. Older people in the earliest stages of Alzheimer’s, before cognitive problems arise, are more likely to suffer a fall than people who are not on track to develop dementia.
Researchers at Washington University School of Medicine in St. Louis have found that, in older people without cognitive problems who experience a fall, the process of neuro-degeneration that leads to Alzheimer’s dementia already may have begun. The findings, available online in the Journal of Alzheimer’s Disease, suggest that older people who have experienced falls should be screened for Alzheimer’s and that new strategies may be needed to reduce the risk of falling for people in the disease’s early stages.
I will repeat, yet again, my extreme interest in the brain aging stemming from the fact that my family has had three cases of dementia or Alzheimer’s Disease. My grandfather on my father’s side, my mother and her sister all had it.
Although it’s normal for brainpower to decline as people age, it’s not inevitable, studies show. Some people remain cognitively sharp into their 80s, 90s, and beyond, defying the common assumption that cognitive decline is a natural part of aging, according to the National Institute on Aging (NIA).
These lucky few, called cognitive super agers, perform demonstrably better on memory tests, such as remembering past events or recalling a list of words, compared with other adults their age. NIA-supported researchers are exploring the factors that set these people apart so the knowledge can be used to help others prevent or reverse age-related cognitive decline.
Working with their colleagues at the University of Pennsylvania, researchers at the University of Kentucky have found that they can differentiate between sub-types of dementia inducing brain disease.
“For the first time we created criteria that could differentiate between frontotemporal dementia (FTD) and a common Alzheimer’s ‘mimic’ called LATE disease,” said Dr. Peter Nelson of the Sanders-Brown Center on Aging at the University of Kentucky. He says they validated the criteria rigorously. The study was recently published in BRAIN: A Journal of Neurology. The first author of the paper was John L. Robinson from the University of Pennsylvania and the corresponding author was Nelson.
Genes and cardiovascular health each contribute in an additive way to a person’s risk of dementia, U.S. researchers including Sudha Seshadri, MD, and Claudia Satizabal, PhD, of The University of Texas Health Science Center at San Antonio (UT Health San Antonio) reported July 20 in the journal Neurology.
The study was conducted in 1,211 participants in the Framingham Heart Study and involved collaborators from Boston University.
Participants with a high genetic risk score based on common genetic variants, including having an allele called apolipoprotein E (APOE) ε4, were at a 2.6-fold higher risk of developing dementia than subjects who had a low risk score and did not carry the APOE ε4 allele.
In the study of people aged over 55, published in Alzheimer’s & Dementia, researchers found ‘repetitive negative thinking’ (RNT) is linked to subsequent cognitive decline as well as the deposition of harmful brain proteins linked to Alzheimer’s.
The researchers say RNT should now be further investigated as a potential risk factor for dementia, and psychological tools, such as mindfulness or meditation, should be studied to see if these could reduce dementia risk.
Lead author Dr Natalie Marchant (UCL Psychiatry) said: “Depression and anxiety in mid-life and old age are already known to be risk factors for dementia. Here, we found that certain thinking patterns implicated in depression and anxiety could be an underlying reason why people with those disorders are more likely to develop dementia.
As the old adage goes, an aspirin a day keeps the doctor away. However, new research shows that an aspirin a day will not keep dementia away.
The ASPREE study, Aspirin in Reducing Events in Elderly, evaluated the use of daily, low-dose aspirin in delaying cognitive decline for healthy older adults. Unfortunately, the study did not find that aspirin had any benefit on reducing memory and thinking problems.
“Aspirin is a commonly used drug known to reduce inflammation.,” explained Joanne Ryan, PhD, who collaborated with her colleagues on ASPREE study. “Since inflammation is a significant factor in Alzheimer’s disease, it formed the basis of the hypothesis that aspirin could be beneficial in helping to reduce the occurrence of cognitive decline.”
The ASPREE study involved more than 19,000 participants, mostly 70 years of age and older, who did not have heart disease or a diagnosis of dementia. Half the participants received 100mg of aspirin daily and half received a placebo. All participants received a series of memory & thinking tests throughout the study.
“At the end of the five year trial, we identified that aspirin had no effect on dementia regardless of ethnicity, age, gender or an individual’s current health.” said Dr. Ryan, head of the Biological Neuropsychiatry and Dementia Unit at Monash University’s School of Public Health and Preventative Medicine in Melbourne, Australia.
The question remains whether aspirin could be beneficial if begun in mid-life, long before Alzheimer’s disease starts to take hold in the brain. Dr. Ryan feels it is possible that the benefits of low-dose aspirin may not be seen for several more years. For that reason, the National Institute on Aging, which funded the ASPREE trial, has sponsored ongoing monitoring of cognitive function and other health measures for the trial’s participants. However, it will be some years before results are known.
“The ASPREE study provides strong evidence that low-dose aspirin will not reduce the risk of Alzheimer’s disease,” said Dr. Ryan. “While the results are disappointing, the findings are very relevant to older people and their physicians and indicate aspirin should not be prescribed solely on the basis of potential cognitive benefits.”
Researchers have found a way to design an antibody that can identify the toxic particles that destroy healthy brain cells – a potential advance in the fight against Alzheimer’s disease.
Their method is able to recognize these toxic particles, known as amyloid-beta oligomers, which are the hallmark of the disease, leading to hope that new diagnostic methods can be developed for Alzheimer’s disease and other forms of dementia.
The team, from the University of Cambridge, University College London and Lund University, designed an antibody which is highly accurate at detecting toxic oligomers and quantifying their numbers. Their results are reported in the Proceedings of the National Academy of Sciences (PNAS).
Inflammation in the brain may be more widely implicated in dementias than was previously thought, suggests new research from the University of Cambridge. The researchers say it offers hope for potential new treatments for several types of dementia.
Inflammation is usually the body’s response to injury and stress – such as the redness and swelling that accompanies an injury or infection. However, inflammation in the brain – known as neuroinflammation – has been recognized and linked to many disorders including depression, psychosis and multiple sclerosis. It has also recently been linked to the risk of Alzheimer’s disease.
In a study published in the journal Brain, a team of researchers at the University of Cambridge set out to examine whether neuroinflammation also occurs in other forms of dementia, which would imply that it is common to many neurodegenerative diseases.
Herewith another entry in our arsenal against that destroyer of lives – Alzheimer’s Disease, from the Tufts Health & Nutrition Letter.
Alzheimer’s disease accounts for 60 to 80 percent of the loss of memory and other cognitive abilities collectively known as dementia. There is no known food or diet that can prevent or cure Alzheimer’s dementia, but diet may help delay onset and slow progression.
What sets Alzheimer’s apart from other forms of dementia is the excessive buildup of beta-amyloid protein fragments into plaques, as well as defective tau proteins that form tangles in the brain. These changes lead to the death of the nerve cells responsible for everything from memory to movement. There are currently no known dietary factors that can impact the formation of these plaques and tangles, but diet may act in other ways to influence Alzheimer’s and other forms of dementia.
Scientists from the Uniformed Services University (USU), Emory University and the University of Vermont have found that cigarette smoking is linked to increased lesions in the brain’s white matter, called white matter hyperintensities. White matter hyperintensities, detected by MRI scan, are associated with cognitive decline and Alzheimer’s disease. These findings may help explain the link between smoking and increased rates of dementia and other forms of cognitive decline.
Being a senior citizen with a family tree containing both Alzheimer’s Disease and dementia, I read everything I can on the subject. Here is the latest from the Global Council on Brain Health (GCBH).
Did you know that taking care of your heart can reduce your risk for memory and thinking problems? A review of medical research conducted by the Global Council on Brain Health recently showed a reduced risk of dementia with improved heart health. So, let’s review their major findings to learn how we can take better care of our hearts and brains. Continue reading →
While there is no known ‘silver bullet’ for Alzheimer’s disease it appears that there may be some ‘luck of the draw’ genetic variants that help.
A DNA study of over 10,000 people by University College of London (UCL) scientists has identified a class of gene variants that appear to protect against Alzheimer’s disease.
The findings, published in Annals of Human Genetics, suggest these naturally occurring gene variants reduce the functioning of proteins called tyrosine phosphatases, which are known to impair the activity of a cell signalling pathway known as PI3K/Akt/GSK-3β. This pathway is important for cell survival.
The research builds on previous studies in mice and rats, which suggested inhibiting the function of these proteins might be protective against Alzheimer’s disease, but this is the first time such an effect has been demonstrated in people.
Researchers believe the PI3K/Akt/GSK-3β signalling pathway could be a key target for therapeutic drugs and the findings also strengthen evidence that other genes could be linked to either elevated or reduced risk of Alzheimer’s disease.
“These results are quite encouraging. It looks as though when naturally-occurring genetic variants reduce the activity of tyrosine phosphatases then this makes Alzheimer’s disease less likely to develop, suggesting that drugs which have the same effect might also be protective,” said the study’s lead author, Professor David Curtis (UCL Genetics Institute).